Gracell announces start of investigator-initiated trial to expand clinical evaluation of FasTCAR-T GC012F into autoimmune disease
GC012F pioneers the use of CD19/BCMA dual-targeting CAR-T in SLE, aiming for deeper and wider depletion of autoantibodies producing B-cells and plasma cells
SAN DIEGO, CA, USA; SUZHOU and SHANGHAI, China I May 15, 2023 I Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer and autoimmune diseases, today announced the initiation of an investigator-initiated trial (IIT) in China of GC012F, the Company’s autologous FasTCAR therapeutic candidate dual-targeting B cell maturation antigen (BCMA) and CD19, for the treatment of refractory SLE.
“Our lead candidate GC012F leverages several next-generation CAR-T technologies including CD19/BCMA dual-targeting and the FasTCAR next-day manufacturing. This cell therapy candidate has demonstrated strong efficacy and consistently favorable safety in the treatment of several hematological malignancies, and we look forward to extending this potentially curative treatment option to patients with autoimmune diseases, such as SLE,” said William Cao, founder, Chairman and Chief Executive Officer of Gracell. “Patients with refractory SLE have limited options to treat their wide-ranging and often debilitating symptoms. This study of GC012F in SLE marks an important next step in GC012F’s development as we look to confirm its potential in autoimmune diseases and prepare the IND submission in both U.S. and China.”
SLE is a chronic autoimmune disease, in which the autoantibodies produced by the immune system attack the patient’s own tissues, causing multi-organ damage. SLE affects over three million people worldwide,[1] with disproportionate burden of disease seen among young women.[2] While immunosuppressants are used as the current standard of care, SLE remains a chronic condition that is difficult to manage, significantly impacts quality of life, and has no cure. Furthermore, refractory/severe SLE could lead to permanent organ damage, resulting in serious morbidity and even death. As such, there is urgent, high unmet medical need for more effective – and even curative – therapies, particularly to help manage refractory SLE.
GC012F has been studied in more than 50 patients across three hematological malignancy indications. In two studies on relapsed/refractory multiple myeloma (RRMM) and newly-diagnosed multiple myeloma (NDMM), GC012F has demonstrated fast, deep and durable responses and achieved 93.1% and 100% overall response rate (ORR), respectively. SLE is a new therapeutic area of interest for Gracell, as CD19 CAR-T has been reported in recent clinical research to be potentially “feasible, tolerable, and highly effective in this indication”.[3]
Gracell’s GC012F represents a novel approach entering human study for refractory SLE and pioneers the use of CD19/BCMA dual-targeting CAR-T in autoimmune disease. By targeting both CD19 and BCMA, GC012F could potentially enable deeper and wider depletion of autoantibodies producing B-cells and plasma cells, hence enhancing therapeutic outcomes in comparison to CD19-only approaches.
GC012F has a proven safety record in patients with RRMM, NDMM and B-NHL. No neurotoxicity or immune effector cell-associated neurotoxicity syndrome (ICANs) has been observed in any patients treated across three studies. 75% of patients in the NDMM study has not experienced cytokine release syndrome (CRS) of any grade, and in the RRMM study, patients experienced mostly low-grade CRS.
The FasTCAR next-day manufacturing platform technology could bring additional benefits to SLE patients as it shortens patient wait time, enhances CAR-T cell fitness, and reduces costs.
For more information on the study, please visit ClinicalTrials.gov using the identifier: NCT05846347.
About GC012F
GC012F is Gracell’s FasTCAR-enabled BCMA/CD19 dual-targeting autologous CAR-T cell therapy, which aims to transform cancer and immunology treatment by driving fast, deep and durable responses with improved safety profile. GC102F is currently being evaluated in trials in multiple myeloma and B-cell non-Hodgkin’s lymphoma (B-NHL), and has demonstrated a consistently strong efficacy and safety profile. In February 2023, Gracell announced regulatory clearance of Investigational New Drug applications in the U.S. and China to commence clinical trials evaluating GC012F for the treatment of relapsed/refractory multiple myeloma. Gracell has also initiated an investigator-initiated trial evaluating GC012F for the treatment of SLE.
About FasTCAR
Introduced in 2017, FasTCAR is Gracell’s revolutionary next-day autologous CAR-T cell manufacturing platform. FasTCAR is designed to lead the next generation of cancer and autoimmune therapy and improve outcomes for patients by enhancing efficacy, reducing costs, and enabling more patients to access critical CAR-T treatment. FasTCAR drastically shortens cell production from weeks to overnight, potentially reducing patient wait times and probability for their disease to progress. Furthermore, FasTCAR T-cells appear younger and are more robust than traditional CAR-T cells, making them more proliferative and effective at killing cancer cells. In November 2022, FasTCAR was named the winner of the Biotech Innovation category of the 2022 Fierce Life Sciences Innovation Awards for its ability to address major industry obstacles.
About Refractory SLE
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which the immune system attacks its own tissues, causing widespread inflammation and tissue damage throughout the body, potentially impacting the joints, skin, brain, lungs, kidneys and blood vessels. SLE affects over 3 million people worldwide,[4] with disproportionate burden of disease seen among young women.[5] Immunosuppressants are the current standard of care, but early study data suggests that CAR-T cell therapy may be a potential treatment option.
About Gracell
Gracell Biotechnologies Inc. (“Gracell”) is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell and gene therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms and SMART CARTM technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com. Follow @GracellBio on LinkedIn.
SOURCE: Gracell Biotechnologies
Post Views: 468
Gracell announces start of investigator-initiated trial to expand clinical evaluation of FasTCAR-T GC012F into autoimmune disease
GC012F pioneers the use of CD19/BCMA dual-targeting CAR-T in SLE, aiming for deeper and wider depletion of autoantibodies producing B-cells and plasma cells
SAN DIEGO, CA, USA; SUZHOU and SHANGHAI, China I May 15, 2023 I Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer and autoimmune diseases, today announced the initiation of an investigator-initiated trial (IIT) in China of GC012F, the Company’s autologous FasTCAR therapeutic candidate dual-targeting B cell maturation antigen (BCMA) and CD19, for the treatment of refractory SLE.
“Our lead candidate GC012F leverages several next-generation CAR-T technologies including CD19/BCMA dual-targeting and the FasTCAR next-day manufacturing. This cell therapy candidate has demonstrated strong efficacy and consistently favorable safety in the treatment of several hematological malignancies, and we look forward to extending this potentially curative treatment option to patients with autoimmune diseases, such as SLE,” said William Cao, founder, Chairman and Chief Executive Officer of Gracell. “Patients with refractory SLE have limited options to treat their wide-ranging and often debilitating symptoms. This study of GC012F in SLE marks an important next step in GC012F’s development as we look to confirm its potential in autoimmune diseases and prepare the IND submission in both U.S. and China.”
SLE is a chronic autoimmune disease, in which the autoantibodies produced by the immune system attack the patient’s own tissues, causing multi-organ damage. SLE affects over three million people worldwide,[1] with disproportionate burden of disease seen among young women.[2] While immunosuppressants are used as the current standard of care, SLE remains a chronic condition that is difficult to manage, significantly impacts quality of life, and has no cure. Furthermore, refractory/severe SLE could lead to permanent organ damage, resulting in serious morbidity and even death. As such, there is urgent, high unmet medical need for more effective – and even curative – therapies, particularly to help manage refractory SLE.
GC012F has been studied in more than 50 patients across three hematological malignancy indications. In two studies on relapsed/refractory multiple myeloma (RRMM) and newly-diagnosed multiple myeloma (NDMM), GC012F has demonstrated fast, deep and durable responses and achieved 93.1% and 100% overall response rate (ORR), respectively. SLE is a new therapeutic area of interest for Gracell, as CD19 CAR-T has been reported in recent clinical research to be potentially “feasible, tolerable, and highly effective in this indication”.[3]
Gracell’s GC012F represents a novel approach entering human study for refractory SLE and pioneers the use of CD19/BCMA dual-targeting CAR-T in autoimmune disease. By targeting both CD19 and BCMA, GC012F could potentially enable deeper and wider depletion of autoantibodies producing B-cells and plasma cells, hence enhancing therapeutic outcomes in comparison to CD19-only approaches.
GC012F has a proven safety record in patients with RRMM, NDMM and B-NHL. No neurotoxicity or immune effector cell-associated neurotoxicity syndrome (ICANs) has been observed in any patients treated across three studies. 75% of patients in the NDMM study has not experienced cytokine release syndrome (CRS) of any grade, and in the RRMM study, patients experienced mostly low-grade CRS.
The FasTCAR next-day manufacturing platform technology could bring additional benefits to SLE patients as it shortens patient wait time, enhances CAR-T cell fitness, and reduces costs.
For more information on the study, please visit ClinicalTrials.gov using the identifier: NCT05846347.
About GC012F
GC012F is Gracell’s FasTCAR-enabled BCMA/CD19 dual-targeting autologous CAR-T cell therapy, which aims to transform cancer and immunology treatment by driving fast, deep and durable responses with improved safety profile. GC102F is currently being evaluated in trials in multiple myeloma and B-cell non-Hodgkin’s lymphoma (B-NHL), and has demonstrated a consistently strong efficacy and safety profile. In February 2023, Gracell announced regulatory clearance of Investigational New Drug applications in the U.S. and China to commence clinical trials evaluating GC012F for the treatment of relapsed/refractory multiple myeloma. Gracell has also initiated an investigator-initiated trial evaluating GC012F for the treatment of SLE.
About FasTCAR
Introduced in 2017, FasTCAR is Gracell’s revolutionary next-day autologous CAR-T cell manufacturing platform. FasTCAR is designed to lead the next generation of cancer and autoimmune therapy and improve outcomes for patients by enhancing efficacy, reducing costs, and enabling more patients to access critical CAR-T treatment. FasTCAR drastically shortens cell production from weeks to overnight, potentially reducing patient wait times and probability for their disease to progress. Furthermore, FasTCAR T-cells appear younger and are more robust than traditional CAR-T cells, making them more proliferative and effective at killing cancer cells. In November 2022, FasTCAR was named the winner of the Biotech Innovation category of the 2022 Fierce Life Sciences Innovation Awards for its ability to address major industry obstacles.
About Refractory SLE
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which the immune system attacks its own tissues, causing widespread inflammation and tissue damage throughout the body, potentially impacting the joints, skin, brain, lungs, kidneys and blood vessels. SLE affects over 3 million people worldwide,[4] with disproportionate burden of disease seen among young women.[5] Immunosuppressants are the current standard of care, but early study data suggests that CAR-T cell therapy may be a potential treatment option.
About Gracell
Gracell Biotechnologies Inc. (“Gracell”) is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell and gene therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms and SMART CARTM technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com. Follow @GracellBio on LinkedIn.
SOURCE: Gracell Biotechnologies
Post Views: 468
